1.Exploring Effect and Mechanisms of Jianpi Huogu Prescription in Treating Steroid-induced Osteonecrosis of Femoral Head via Regulating Adipogenesis, Osteogenesis, and Angiogenesis by Animal and Cell Experiments
Chupei ZHENG ; Qianqian YAN ; Jialin WANG ; Qingyu ZHAO ; Jianle YANG ; Na LIN ; Tao SU ; Weiheng CHEN ; Chunfang LIU ; Yuge LI
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(24):35-50
ObjectiveTo investigate the effects and mechanisms of Jianpi Huogu prescription (JPHGP) in treating steroid-induced osteonecrosis of the femoral head (SONFH) by suppressing adipogenesis while promoting osteogenesis and angiogenesis, through an integrated approach combining animal experiments, cell experiments, and network pharmacology. MethodsIn the animal experiments, 60 Sprague-Dawley (SD) rats (6-8 weeks old) were randomly assigned into six groups: blank control, model, low-, medium-, and high-dose (2.5, 5, and 10 g·kg-1, respectively) JPHGP, and Tongluo Shenggu prescription (TLSG, 0.54 g·kg-1) groups. The SONFH model was established with methylprednisolone sodium succinate (MPS) and lipopolysaccharide (LPS). After 8 weeks of treatment, the therapeutic effects were evaluated by mechanical pain threshold testing, inclined plate test, serum lipid parameters, femoral head histopathology and imaging analysis, and ink perfusion assay. In the cell experiments, bone marrow mesenchymal stem cells (BMSCs) and endothelial progenitor cells (EPCs) were treated with dexamethasone (DEX, 5 mg·L-1) to simulate the SONFH pathological environment. The direct effects of JPHGP (1, 10, and 100 μg·L-1) on adipogenic/osteogenic differentiation of BMSCs and angiogenic function of EPCs were observed. Transwell and scratch assays were employed to evaluate the migration of BMSCs and EPCs, respectively. Osteogenic differentiation was evaluated by alkaline phosphatase activity and Alizarin Red staining. Adipogenic differentiation was detected by oil red O staining, and angiogenic capacity was measured by tube formation assay. To decipher the therapeutic mechanisms, network pharmacology analysis was performed on BMSC transcriptome data from the GEO database, which was combined with literature research to predict core targets of JPHGP against SONFH, followed by validation in vivo and in vitro. ResultsThe animal experiment results showed that compared with the blank control group, model rats exhibited decreased mechanical pain thresholds and maximal inclination angles (P<0.01), reduced osteocyte counts with increased empty lacunae in the femoral head (P<0.01), decreased bone mineral density (BMD), trabecular thickness (Tb.Th), trabecular number (Tb.N), and bone volume fraction (BV/TV), increased trabecular separation (Tb.Sp) and bone surface/bone volume (BS/BV) ratio (P<0.01), diminished ink perfusion area (P<0.01), elevated levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), and apolipoprotein B (ApoB), and declined levels of high-density lipoprotein (HDL) and apolipoprotein A1 (ApoA1) (P<0.01). Compared with the model group, JPHGP 5 and 10 g·kg-1 could significantly increase the mechanical pain threshold and the maximum tilt angle of the inclined plate (P<0.05, P<0.01), increase the number of osteocytes in the femoral head, decrease the number of empty bone lacunae (P<0.05, P<0.01), increase BMD, Tb.Th, Tb.N and BV/TV, decrease Tb.Sp and BS/BV (P<0.05, P<0.01), increase the ink perfusion area in the femoral head (P<0.01), decrease the contents of serum TG, TC, LDL and ApoB, and increase the contents of HDL and ApoA1 (P<0.05, P<0.01). The cell experiment results showed that DEX (5 mg·L-1) promoted the adipogenesis of BMSCs while inhibiting the migration and osteogenesis of BMSCs and the angiogenesis of EPCs (P<0.01). JPHGP (1, 10, and 100 μg·L-1) dose-dependently enhanced cell migration, restored osteogenic and tube-forming capacities, and suppressed adipogenic differentiation (P<0.05, P<0.01). Network pharmacology and transcriptomic analysis predicted phosphodiesterase 10A (PDE10A), bone morphogenetic protein 2 (BMP2), and vascular endothelial growth factor (VEGF) as key targets of JPHGP in intervening in DEX-BMSCs. DEX suppressed the expression of PDE10A, BMP2, and VEGF while upregulating the expression of cyclic adenosine monophosphate (cAMP) and peroxisome proliferator-activated receptor-γ (PPARγ) in BMSCs (P<0.01). JPHGP reversed these effects dose-dependently (P<0.05, P<0.01), which, however, were abolished by PDE10A inhibitors or PPARγ agonists. These findings were further confirmed in the necrotic femoral head tissue from SONFH rats. Additionally, JPHGP elevated the expression of fatty acid-binding protein 4 (FABP4, a late adipogenic marker), Collagen Ⅰ(ColⅠ), and CD31 (a vascular endothelial cell-specific marker) (P<0.05, P<0.01). ConclusionJPHGP activates PDE10A to degrade cAMP, thereby suppressing PPARγ production and subsequently promoting BMP2 and VEGF generation, ultimately achieving multi-target regulation of adipogenesis, osteogenesis, angiogenesis to reconstruct the lipid-bone-blood homeostasis. This study provides a scientific basis for the effective treatment of early-stage osteonecrosis of the femoral head.

Result Analysis
Print
Save
E-mail